Search Results 631-640 of 14768 for anti-TNF drugs

  1. Norethindrone, Ethinyl Estradiol, And Ferrous Fumarate (Oral Route) Before Using - Mayo Clinic

    Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

  2. An Extension Study Monitoring the Safety of Patients with Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 - Mayo Clinic

    Drugs & Supplements A-Z · Health Books · Healthy ... Use of TNF antagonists;; Use of antagonists of ... Use of anti-adhesion molecules (e.g., anti-MAdCAM-1).

  3. Clinical Trials - Mayo Clinic Research

    ... Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk for ...

  4. Vasodilators - Mayo Clinic

    Vasodilators are medicines that open, also called dilate, blood vessels. Vasodilators affect the muscles in the walls of the arteries and veins.

  5. Anti-VEGF vs. Prompt Vitrectomy for VH From PDR - Mayo Clinic

    Intravitreous anti-vascular endothelial growth factor (anti-VEGF) therapy alone or vitrectomy combined with intraoperative PRP each provide the opportunity to ...

  6. Teprotumumab-Trbw (Intravenous Route) Before Using - Mayo Clinic

    Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Drug Interactions. Although certain medicines should ...

  7. Trastuzumab-Anns (Intravenous Route) Description and Brand Names - Mayo Clinic

    Descriptions. Trastuzumab-anns injection is used together with other cancer medicines (eg, doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, or ...

  8. Antihemophilic Factor (Intravenous Route) Side Effects - Mayo Clinic

    Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...

  9. Non-Hodgkin's Lymphoma Clinical Trials - Mayo Clinic Research

    Rituximab, an anti-CD20 chimeric antibody, was approved by the United States Food and Drug Administration in 1998 for the treatment of patients with relapsed ...

  10. Anticholinergics And Antispasmodics (Oral Route, Parenteral Route, Rectal Route, Transdermal Route) Side Effects - Mayo Clinic

    Side Effects. Drug information provided by: Merative, Micromedex®. Along with its needed effects, a medicine may cause some unwanted effects. Although not ...